News Focus
News Focus
icon url

biomaven0

10/27/11 12:41 PM

#129593 RE: jq1234 #129588

Tofacitinib hits JAK3, it works out fine.



Doesn't imply that if JAK3 is all you hit (as VRTX does) that you will be OK. It might turn out to be a dosage issue - you can partially inhibit JAK1 and JAK3 say, or you can more fully inhibit JAK3 by itself to get the same efficacy, but maybe with more problems with infections.

When I was talking about the INCY compound I did not mean their myelofibrosis compound - I meant their RA version:

http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-newsArticle&ID=1494997&highlight=

Peter